PT  - JOURNAL ARTICLE
AU  - Delport, D.
AU  - Muellenmeister, A.M.
AU  - MacKechnie, G.
AU  - Vaccher, S.
AU  - Mengistu, T.
AU  - Hogan, D.
AU  - Abeysuriya, R.G.
AU  - Scott, N.
TI  - Estimating the historical impact of outbreak response immunization programs across 210 outbreaks in LMICs
AID  - 10.1101/2024.06.02.24308241
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.02.24308241
4099  - http://medrxiv.org/content/early/2024/06/03/2024.06.02.24308241.short
4100  - http://medrxiv.org/content/early/2024/06/03/2024.06.02.24308241.full
AB  - Background Outbreaks of vaccine-preventable diseases continue to occur in low- and middle-income countries (LMICs), requiring outbreak response immunization (ORI) programs for containment. To inform future investment decisions, this study aimed to estimate the cases, deaths, disability-adjusted life years (DALYs), and societal economic costs averted by past ORI programs. Outbreaks of measles, Ebola, yellow fever, cholera, and meningococcal meningitis in LMICs between 2000-2023 were considered.Methods 210 outbreaks (51 measles, 40 cholera, 88 yellow fever, 24 meningitis, 7 Ebola) were identified with sufficient data for analysis. Agent-based models were calibrated for each disease such that after controlling for baseline vaccine coverage, ORI initiation time, speed of vaccine delivery, environmental variables, or endemic prevalence of the disease, observed outbreaks were within the distribution of simulated outbreaks. A status-quo and no ORI scenario were compared for each outbreak.Findings Across 210 outbreaks, ORI programs are estimated to have averted 5·81M [95% uncertainty interval 5·75M–5·87M] cases (4·01M measles, 283K cholera, 1·50M yellow fever, 21·3K meningitis, 820 Ebola), 327K [317K–338K] deaths (20.0K measles, 5215 cholera, 300K yellow fever, 1599 meningitis, 381 Ebola), 14·6M [14·1M–15·1M] DALYs (1·27M measles, 220K cholera, 13·0M yellow fever, 113K meningitis, 16·6K Ebola), and US$31·7B [29·0B–34·9B] (US$710M measles, US$156M cholera, US$30·7B yellow fever, US$97·6M meningitis, US$6·72M Ebola) in societal economic costs. In general, the more rapidly the ORI was initiated the greater the impact.Interpretation ORI programs are critical for reducing the health and economic impacts of outbreaks of vaccine-preventable diseases.Funding Gavi,the Vaccine Alliance.Competing Interest StatementD.D. has received funding for a PhD scholarship from the National Health and Medical Research Council in Australia. This work was funded by Gavi, the Vaccine Alliance. T.M. and D.H. have positions at Gavi; they have contributed to the study design, project administration, analysis validation, and the review and editing of the manuscript.Funding StatementThis study was funded by Gavi, the Vaccine Alliance.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.